The effect of selegiline on the peripheral pharmacokinetics of levodopa in young volunteers
- PMID: 8554944
- PMCID: PMC1365161
- DOI: 10.1111/j.1365-2125.1995.tb04564.x
The effect of selegiline on the peripheral pharmacokinetics of levodopa in young volunteers
Abstract
The plasma pharmacokinetics of levodopa were studied in eight healthy young subjects following an i.v. infusion of 50 mg over 5 min. Subjects were studied on two occasions in random order following treatment with carbidopa; on one occasion they were pretreated with selegiline (four doses of 10 mg over the preceding 3 days) and on the other with a placebo. The mean plasma concentration-time curves on each occasion were essentially superimposable and there were no significant differences in any calculated pharmacokinetic parameter. Selegiline does not significantly alter the distribution or elimination of levodopa from plasma.
Similar articles
-
Intravenous levodopa administration in humans based on a two-compartment kinetic model.J Neurosci Methods. 2007 Jan 30;159(2):300-7. doi: 10.1016/j.jneumeth.2006.07.010. Epub 2006 Aug 24. J Neurosci Methods. 2007. PMID: 16934332 Clinical Trial.
-
The effects of co-administration of benzhexol on the peripheral pharmacokinetics of oral levodopa in young volunteers.Br J Clin Pharmacol. 1996 Apr;41(4):331-7. doi: 10.1046/j.1365-2125.1996.32311.x. Br J Clin Pharmacol. 1996. PMID: 8730980 Free PMC article. Clinical Trial.
-
Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.Br J Clin Pharmacol. 2004 Nov;58 Suppl 1(Suppl 1):41-9. doi: 10.1111/j.1365-2125.2004.01799.x. Br J Clin Pharmacol. 2004. PMID: 15496222 Free PMC article. Clinical Trial.
-
Clinical pharmacokinetics of cabergoline.Clin Pharmacokinet. 2003;42(7):633-45. doi: 10.2165/00003088-200342070-00003. Clin Pharmacokinet. 2003. PMID: 12844325 Review.
-
Pharmacokinetics of continuous-release carbidopa/levodopa.Clin Neuropharmacol. 1994;17 Suppl 2:S1-6. Clin Neuropharmacol. 1994. PMID: 9358189 Review.
Cited by
-
Antiparkinsonian Agents : Clinically Significant Drug Interactions and Adverse Effects, and Their Management.CNS Drugs. 1998 Apr;9(4):291-310. doi: 10.2165/00023210-199809040-00005. CNS Drugs. 1998. PMID: 27521014
-
The Human Experience with Intravenous Levodopa.Front Pharmacol. 2016 Jan 6;6:307. doi: 10.3389/fphar.2015.00307. eCollection 2015. Front Pharmacol. 2016. PMID: 26779024 Free PMC article. Review.
-
Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update.Clin Pharmacokinet. 2006;45(2):109-36. doi: 10.2165/00003088-200645020-00001. Clin Pharmacokinet. 2006. PMID: 16485914 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources